losartan has been researched along with Metabolic Syndrome in 32 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study showed that in patients with hypertension and metabolic syndrome, both losartan and eprosartan have a neutral effect on fasting and postfructose load serum uric acid concentration and its urinary excretion." | 9.41 | Losartan and Eprosartan Induce a Similar Effect on the Acute Rise in Serum Uric Acid Concentration after an Oral Fructose Load in Patients with Metabolic Syndrome. ( Majer, J; Masajtis-Zagajewska, A; Nowicki, M, 2021) |
| "To evaluate effects of 6-month therapy with losartan in combination with indapamide on a clinical course, immunological, metabolic parameters, left ventricular function, exercise tolerance and quality of life in patients with coronary heart disease (CHD) associated with metabolic syndrome (MS)." | 9.14 | [Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus]. ( Bolotskaia, LA; Derbeneva, NV; Frants, MV; Kuznetsova, AV; Lukinov, AV; Maianskaia, SD; Shilov, SN; Stepacheva, TA; Tepliakov, AT; Vdovina, TV, 2009) |
| "The impact of an ARB, with or without hydrochlorothiazide (HCTZ), on glycaemic factors and the risk for developing diabetes in hypertensive patients with the metabolic syndrome have not been fully assessed." | 9.14 | A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome. ( Bastien, N; Hamet, P; Longo, N; Racine, N; Sampalis, JS, 2010) |
| "The aim of this study was to compare the effect of aliskiren and losartan on fibrinolysis and insulin sensitivity (IS) in hypertensive patients with metabolic syndrome." | 9.14 | Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. ( Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Zoppi, A, 2010) |
| "The aim of the study was to evaluate therapeutic effects of losartan on intravascular thrombocyte activity (ITA) in patients suffering from arterial hypertension with metabolic syndrome (MS)." | 9.13 | [Losartan for the correction of thrombocyte activity in patients suffering from arterial hypertension with metabolic syndrome]. ( Kumova, TA; medvedev, iN; Simonenko, VB, 2008) |
| " To test telmisartan's clinical importance, we here investigated its effect on insulin resistance in hypertensive patients with metabolic syndrome (MetS) in comparison with another ARB, losartan." | 9.12 | Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. ( Bahadir, MA; Bahadir, O; Oguz, A; Uzunlulu, M, 2007) |
| "To evaluate 24-hour efficacy of losartan in patients with newly diagnosed hypertension and metabolic syndrome using the parametric population RDH index and normalized smoothness index." | 7.76 | [The normalized smoothness index and parametric population RDH index of losartan in patients with newly diagnosed hypertension and metabolic syndrome]. ( Frána, P; Plachý, M; Rihácek, I; Schwarz, D; Soucek, M, 2010) |
| " We investigated long-term effects of losartan on serum concentrations of total and HMW adiponectin in hypertensive patients with metabolic syndrome (MS) by serial measurements over 6 months." | 7.74 | Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome. ( Aso, Y; Hara, K; Inoue, T; Inukai, T; Nakano, T; Node, K; Sakai, Y; Shimizu, M; Takayanagi, K; Takebayashi, K; Uchida, T, 2008) |
| " We have investigated the effects of a long-acting calcium antagonist, benidipine, and an angiotensin AT(1) receptor antagonist, losartan, on the vascular damage observed in OLETF rats, an animal model of metabolic syndrome." | 7.74 | Comparison of vasculoprotective effects of benidipine and losartan in a rat model of metabolic syndrome. ( Furuta, K; Hongo, M; Ishizaka, N; Koike, K; Matsuzaki, G; Nagai, R; Saito, K; Sakurai, R, 2008) |
| "The study showed that in patients with hypertension and metabolic syndrome, both losartan and eprosartan have a neutral effect on fasting and postfructose load serum uric acid concentration and its urinary excretion." | 5.41 | Losartan and Eprosartan Induce a Similar Effect on the Acute Rise in Serum Uric Acid Concentration after an Oral Fructose Load in Patients with Metabolic Syndrome. ( Majer, J; Masajtis-Zagajewska, A; Nowicki, M, 2021) |
| "Salt-sensitive hypertension is a characteristic of the metabolic syndrome." | 5.38 | Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. ( Araki, H; Araki, S; Chin-Kanasaki, M; Deji, N; Haneda, M; Isshiki, K; Kashiwagi, A; Koya, D; Kume, S; Maegawa, H; Nishiyama, A; Tanaka, Y; Uzu, T, 2012) |
| "A total of 439 hypertensive patients with metabolic syndrome and/or diabetes mellitus were randomized to 2 groups: group 1--ramipril (ACE-I) or perindopril and group 2--losartan (ARB)." | 5.19 | Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the M E D I N A study). ( Soucek, M; Spinar, J; Vitovec, J, 2014) |
| "To evaluate effects of 6-month therapy with losartan in combination with indapamide on a clinical course, immunological, metabolic parameters, left ventricular function, exercise tolerance and quality of life in patients with coronary heart disease (CHD) associated with metabolic syndrome (MS)." | 5.14 | [Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus]. ( Bolotskaia, LA; Derbeneva, NV; Frants, MV; Kuznetsova, AV; Lukinov, AV; Maianskaia, SD; Shilov, SN; Stepacheva, TA; Tepliakov, AT; Vdovina, TV, 2009) |
| "The impact of an ARB, with or without hydrochlorothiazide (HCTZ), on glycaemic factors and the risk for developing diabetes in hypertensive patients with the metabolic syndrome have not been fully assessed." | 5.14 | A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome. ( Bastien, N; Hamet, P; Longo, N; Racine, N; Sampalis, JS, 2010) |
| "The aim of this study was to compare the effect of aliskiren and losartan on fibrinolysis and insulin sensitivity (IS) in hypertensive patients with metabolic syndrome." | 5.14 | Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. ( Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Zoppi, A, 2010) |
| "The aim of the study was to evaluate therapeutic effects of losartan on intravascular thrombocyte activity (ITA) in patients suffering from arterial hypertension with metabolic syndrome (MS)." | 5.13 | [Losartan for the correction of thrombocyte activity in patients suffering from arterial hypertension with metabolic syndrome]. ( Kumova, TA; medvedev, iN; Simonenko, VB, 2008) |
| " STAR-LET was a 6-month extension of the Study of Trandolapril/Verapamil SR and Insulin Resistance (STAR), which assessed the effects of a fixed-dose renin-angiotensin system inhibitor (RASI)/hydrochlorothiazide (HCTZ) combination on changes in 2-hour oral glucose tolerance test (OGTT) results." | 5.13 | Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. ( Bacher, P; Bakris, G; Champion, A; Molitch, M; Sarafidis, P; Sowers, JR; Zhou, Q, 2008) |
| " To test telmisartan's clinical importance, we here investigated its effect on insulin resistance in hypertensive patients with metabolic syndrome (MetS) in comparison with another ARB, losartan." | 5.12 | Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. ( Bahadir, MA; Bahadir, O; Oguz, A; Uzunlulu, M, 2007) |
| "Recently, much attention of medical professionals is directed to correlations between hyperuricemia, arterial hypertension, metabolic syndrome and renal affection because of the evidence that elevated blood level of uric acid raises the risk of cardiovascular complications not only in arterial hypertension and metabolic syndrome but also in diabetes mellitus type 2, coronary heart disease, congestive heart failure and renal dysfunction." | 4.87 | [Lozartan potential in hyperuricemia correction]. ( , 2011) |
| " In other rats, glucose, insulin, uric acid, and insulin sensitivity index, were determined before and after fructose or lipoic acid plus fructose." | 3.79 | A single oral dose of fructose induces some features of metabolic syndrome in rats: role of oxidative stress. ( Hong, E; Moreno, JA, 2013) |
| "To evaluate 24-hour efficacy of losartan in patients with newly diagnosed hypertension and metabolic syndrome using the parametric population RDH index and normalized smoothness index." | 3.76 | [The normalized smoothness index and parametric population RDH index of losartan in patients with newly diagnosed hypertension and metabolic syndrome]. ( Frána, P; Plachý, M; Rihácek, I; Schwarz, D; Soucek, M, 2010) |
| " We investigated long-term effects of losartan on serum concentrations of total and HMW adiponectin in hypertensive patients with metabolic syndrome (MS) by serial measurements over 6 months." | 3.74 | Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome. ( Aso, Y; Hara, K; Inoue, T; Inukai, T; Nakano, T; Node, K; Sakai, Y; Shimizu, M; Takayanagi, K; Takebayashi, K; Uchida, T, 2008) |
| " We explored, in a post hoc analysis, whether MetS predicts cardiovascular events in hypertensive patients with electrocardiographic left ventricular hypertrophy (ECG-LVH) in the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study." | 3.74 | Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. ( Dahlöf, B; de Simone, G; Devereux, RB; Hille, DA; Ibsen, H; Kjeldsen, SE; Lyle, PA; Olsen, MH; Wachtell, K, 2007) |
| " We have investigated the effects of a long-acting calcium antagonist, benidipine, and an angiotensin AT(1) receptor antagonist, losartan, on the vascular damage observed in OLETF rats, an animal model of metabolic syndrome." | 3.74 | Comparison of vasculoprotective effects of benidipine and losartan in a rat model of metabolic syndrome. ( Furuta, K; Hongo, M; Ishizaka, N; Koike, K; Matsuzaki, G; Nagai, R; Saito, K; Sakurai, R, 2008) |
| "Patients with the metabolic syndrome have three or more of five cardiovascular risk factors and increased oxidative stress, arterial stiffness and pressor responses to exercise, which may contribute to their threefold greater risk for coronary heart disease." | 2.71 | Angiotensin receptor blockade improves arterial distensibility and reduces exercise-induced pressor responses in obese hypertensive patients with the metabolic syndrome. ( Egan, BM; Jesri, A; Morrow, JD; Nashar, K; Nguyen, JP, 2004) |
| "The potential benefit for treatment of the metabolic syndrome, cardiovascular protection, and prevention of related end-organ complications could be of immense clinical value." | 2.43 | Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. ( Pershadsingh, HA, 2006) |
| "Proteinuria is a sign of established kidney damage and plays a direct pathogenic role in the progression of renal and cardiovascular disease." | 2.43 | Time to abandon microalbuminuria? ( Remuzzi, G; Ruggenenti, P, 2006) |
| "In patients with diabetic kidney disease (DKD), the estimated glomerular filtration rate (eGFR) or creatinine clearance rate (Ccr) is always used as an index of decline in renal function." | 1.91 | Unilateral nephrectomized SHR/NDmcr-cp rat shows a progressive decline of glomerular filtration with tubular interstitial lesions. ( Fukui, K; Inagaki, K; Maekawa, M; Miyajima, K; Ohta, T; Shinozaki, Y; Toyoda, K; Uno, K; Yoshiuchi, H, 2023) |
| "Salt-sensitive hypertension is a characteristic of the metabolic syndrome." | 1.38 | Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. ( Araki, H; Araki, S; Chin-Kanasaki, M; Deji, N; Haneda, M; Isshiki, K; Kashiwagi, A; Koya, D; Kume, S; Maegawa, H; Nishiyama, A; Tanaka, Y; Uzu, T, 2012) |
| "Metabolic syndrome has emerged as the major cause of atherosclerosis." | 1.33 | Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP kinase, and matrix expressions in obesity. ( Huang, KT; Natarajan, R; Rodríguez-Iturbe, B; Shahkarami, A; Vaziri, ND; Xu, ZG, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (50.00) | 29.6817 |
| 2010's | 14 (43.75) | 24.3611 |
| 2020's | 2 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Masajtis-Zagajewska, A | 1 |
| Majer, J | 1 |
| Nowicki, M | 1 |
| Shinozaki, Y | 1 |
| Fukui, K | 1 |
| Maekawa, M | 1 |
| Toyoda, K | 1 |
| Yoshiuchi, H | 1 |
| Inagaki, K | 1 |
| Uno, K | 1 |
| Miyajima, K | 1 |
| Ohta, T | 1 |
| Soler, A | 1 |
| Hunter, I | 1 |
| Joseph, G | 1 |
| Hutcheson, R | 1 |
| Hutcheson, B | 1 |
| Yang, J | 1 |
| Zhang, FF | 1 |
| Joshi, SR | 1 |
| Bradford, C | 1 |
| Gotlinger, KH | 1 |
| Maniyar, R | 1 |
| Falck, JR | 1 |
| Proctor, S | 1 |
| Schwartzman, ML | 1 |
| Gupte, SA | 1 |
| Rocic, P | 1 |
| Spinar, J | 1 |
| Vitovec, J | 1 |
| Soucek, M | 2 |
| Kho, MC | 1 |
| Lee, YJ | 1 |
| Park, JH | 1 |
| Kim, HY | 1 |
| Yoon, JJ | 1 |
| Ahn, YM | 1 |
| Tan, R | 1 |
| Park, MC | 1 |
| Cha, JD | 1 |
| Choi, KM | 1 |
| Kang, DG | 1 |
| Lee, HS | 1 |
| Skibitsky, VV | 1 |
| Fendrikova, AV | 1 |
| Pyhalova, NE | 1 |
| Sirotenko, DV | 1 |
| Uchida, T | 1 |
| Shimizu, M | 1 |
| Sakai, Y | 1 |
| Nakano, T | 1 |
| Hara, K | 1 |
| Takebayashi, K | 1 |
| Inoue, T | 1 |
| Node, K | 1 |
| Inukai, T | 1 |
| Takayanagi, K | 1 |
| Aso, Y | 1 |
| Georgescu, EF | 1 |
| Tepliakov, AT | 1 |
| Maianskaia, SD | 1 |
| Bolotskaia, LA | 1 |
| Vdovina, TV | 1 |
| Stepacheva, TA | 1 |
| Kuznetsova, AV | 1 |
| Lukinov, AV | 1 |
| Derbeneva, NV | 1 |
| Frants, MV | 1 |
| Shilov, SN | 1 |
| Rossi, GP | 1 |
| Ishizaka, N | 2 |
| Hongo, M | 2 |
| Matsuzaki, G | 2 |
| Furuta, K | 2 |
| Saito, K | 2 |
| Sakurai, R | 2 |
| Sakamoto, A | 1 |
| Koike, K | 2 |
| Nagai, R | 2 |
| Racine, N | 1 |
| Hamet, P | 1 |
| Sampalis, JS | 1 |
| Longo, N | 1 |
| Bastien, N | 1 |
| Huang, F | 1 |
| Lezama, MA | 1 |
| Ontiveros, JA | 1 |
| Bravo, G | 1 |
| Villafaña, S | 1 |
| del-Rio-Navarro, BE | 1 |
| Hong, E | 2 |
| Fogari, R | 1 |
| Zoppi, A | 1 |
| Mugellini, A | 1 |
| Lazzari, P | 1 |
| Derosa, G | 1 |
| Beloborodova, AV | 1 |
| Morozova, TE | 1 |
| Shilov, EM | 1 |
| Rihácek, I | 1 |
| Frána, P | 1 |
| Schwarz, D | 1 |
| Plachý, M | 1 |
| Kong, X | 1 |
| Zhang, DY | 1 |
| Wu, HB | 1 |
| Li, FX | 1 |
| Deji, N | 1 |
| Kume, S | 1 |
| Araki, S | 1 |
| Isshiki, K | 1 |
| Araki, H | 1 |
| Chin-Kanasaki, M | 1 |
| Tanaka, Y | 1 |
| Nishiyama, A | 1 |
| Koya, D | 1 |
| Haneda, M | 1 |
| Kashiwagi, A | 1 |
| Maegawa, H | 1 |
| Uzu, T | 1 |
| Moreno, JA | 1 |
| Nashar, K | 1 |
| Nguyen, JP | 1 |
| Jesri, A | 1 |
| Morrow, JD | 1 |
| Egan, BM | 1 |
| Pershadsingh, HA | 1 |
| Vaziri, ND | 1 |
| Xu, ZG | 1 |
| Shahkarami, A | 1 |
| Huang, KT | 1 |
| Rodríguez-Iturbe, B | 1 |
| Natarajan, R | 1 |
| Baumgart, P | 1 |
| Ruggenenti, P | 1 |
| Remuzzi, G | 1 |
| Yoshizumi, M | 1 |
| Ishizawa, K | 1 |
| Izawa, Y | 1 |
| Tamaki, T | 1 |
| Bahadir, O | 1 |
| Uzunlulu, M | 1 |
| Oguz, A | 1 |
| Bahadir, MA | 1 |
| de Simone, G | 1 |
| Olsen, MH | 1 |
| Wachtell, K | 1 |
| Hille, DA | 1 |
| Dahlöf, B | 1 |
| Ibsen, H | 1 |
| Kjeldsen, SE | 1 |
| Lyle, PA | 1 |
| Devereux, RB | 1 |
| Petkow-Dimitrow, P | 1 |
| Simonenko, VB | 1 |
| medvedev, iN | 1 |
| Kumova, TA | 1 |
| Bakris, G | 1 |
| Molitch, M | 1 |
| Zhou, Q | 1 |
| Sarafidis, P | 1 |
| Champion, A | 1 |
| Bacher, P | 1 |
| Sowers, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Losartan and Eprosartan Induce a Similar Effect on Oral Fructose-induced Rise in Serum Uric Acid Concentration in Patients With Metabolic Syndrome[NCT04954560] | 16 participants (Actual) | Interventional | 2008-01-01 | Completed | |||
| Evaluation of the Efficacy of Chinese Herbal Medicine in Patients With Obesity: a Retrospective Study[NCT04481464] | 500 participants (Anticipated) | Observational | 2020-11-01 | Not yet recruiting | |||
| 52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ, 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome[NCT00546052] | Phase 3 | 1,738 participants (Actual) | Interventional | 2005-09-01 | Completed | ||
| [NCT00005474] | 1,063 participants (Actual) | Observational | 1996-09-30 | Completed | |||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Absolute Change in C Reactive Protein Between Baseline and 52 week assessments: C Reactive Protein 52 weeks - C Reactive Protein Baseline. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mg/L (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -0.36 |
Absolute Change in Uric Acid Between Baseline and 52 week assessments: Uric Acid 52 weeks - Uric Acid Baseline. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mmol/L (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -19.17 |
Absolute change in Body Mass Index Baseline and 52 week assessments (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Kg/m2 (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -7.3 |
Absolute change in Diastolic Blood Pressure between baseline and 52 week assessments. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mm Hg (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -9.84 |
Absolute Change in Fasting Blood Glucose Measurements between Baseline and 52 week assessments. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mmol/L (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 0.02 |
Absolute Change in Hemoglobin A1c between 52 week measurement and baseline value. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent (Median) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 0.04 |
Absolute change in Systolic Blood Pressure between baseline and 52 week assessments. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mm Hg (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -16.95 |
Absolute change in Waist Circumference between baseline and 52 week assessments (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | cm (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -1.28 |
Percent Change in HDL-C Between Baseline and 52 week assessments: 100% x [(HDL-C 52 Weeks - HDL-C 52 Baseline) / (HDL-C Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 0.21 |
Percent Change in LDL-C Between Baseline and 52 week assessments: 100% x [(LDL-C 52 Weeks - LDL-C Baseline) / (LDL-C Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -1.49 |
Percent Change in Total Cholesterol Between Baseline and 52 week assessments: 100% x [(Total Cholesterol 52 weeks - Total Cholesterol Baseline) / (Total Cholesterol Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -2.98 |
Percent Change in Triglycerides Between Baseline and 52 week assessments: 100% x [(Triglycerides 52 Weeks - Triglycerides Baseline) / (Triglycerides Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Median) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 1.09 |
Target Blood Pressure defined as Systolic Blood Pressure/Diastolic Blood Pressure ≤ 140/90 mm Hg at 52 weeks (NCT00546052)
Timeframe: 52 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Achieved Target Blood Pressure | Did NOT achieve target Blood Pressure | |
| Overall Intend to Treat | 1200 | 514 |
| Overall Per Protocol | 1200 | 311 |
| Overall Total | 1200 | 538 |
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
6 reviews available for losartan and Metabolic Syndrome
| Article | Year |
|---|---|
Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Fat | 2008 |
[Lozartan potential in hyperuricemia correction].
Topics: Antihypertensive Agents; Humans; Hypertension; Hyperuricemia; Losartan; Metabolic Syndrome; Uric Aci | 2011 |
Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Tri | 2006 |
Time to abandon microalbuminuria?
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; | 2006 |
[Intracellular signal transduction of vascular injury in insulin resistance].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; | 2006 |
[New therapeutic targets for ACE inhibitors and angiotensin receptor blockers].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotens | 2007 |
10 trials available for losartan and Metabolic Syndrome
| Article | Year |
|---|---|
Losartan and Eprosartan Induce a Similar Effect on the Acute Rise in Serum Uric Acid Concentration after an Oral Fructose Load in Patients with Metabolic Syndrome.
Topics: Acrylates; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyp | 2021 |
Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the M E D I N A study).
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2014 |
[Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiotonic Agents; C | 2009 |
A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Glu | 2010 |
Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome.
Topics: Adolescent; Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure; Female; Fibrinolysis; Fuma | 2010 |
[An experience of the use of angiotensin II receptor blocker losartan in patients with metabolic syndrome and chronic kidney disease].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Blood Pressure | 2010 |
Angiotensin receptor blockade improves arterial distensibility and reduces exercise-induced pressor responses in obese hypertensive patients with the metabolic syndrome.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biomarkers; Blood Pressure; Choles | 2004 |
Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Glucose; Bloo | 2007 |
[Losartan for the correction of thrombocyte activity in patients suffering from arterial hypertension with metabolic syndrome].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cholesterol, LDL; Drug Administration Schedule; Fema | 2008 |
Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study.
Topics: Analysis of Variance; Chi-Square Distribution; Diabetes Mellitus; Diuretics; Female; Glucose Toleran | 2008 |
16 other studies available for losartan and Metabolic Syndrome
| Article | Year |
|---|---|
Unilateral nephrectomized SHR/NDmcr-cp rat shows a progressive decline of glomerular filtration with tubular interstitial lesions.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Losartan; Metabolic Syndrome; Rats; Rats | 2023 |
Elevated 20-HETE in metabolic syndrome regulates arterial stiffness and systolic hypertension via MMP12 activation.
Topics: Animals; Blood Pressure; Collagen Type I; Collagen Type III; Compliance; Cytochrome P-450 CYP4A; Cyt | 2018 |
Fermented Red Ginseng Potentiates Improvement of Metabolic Dysfunction in Metabolic Syndrome Rat Models.
Topics: Adipocytes; Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Blood Pressur | 2016 |
[The Effectiveness of Combination Antihypertensive Therapy in Women With Hypothyroidism and the Metabolic Syndrome].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dihydrop | 2016 |
Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome.
Topics: Adiponectin; Aged; Antihypertensive Agents; Female; Humans; Hypertension; Losartan; Male; Metabolic | 2008 |
Losartan metabolite EXP3179: an AT1-receptor-independent treatment strategy for patients with the metabolic syndrome?
Topics: Angiotensin II Type 1 Receptor Blockers; Cyclooxygenase 2 Inhibitors; Dinoprost; Humans; Intercellul | 2009 |
Effects of the AT(1) receptor blocker losartan and the calcium channel blocker benidipine on the accumulation of lipids in the kidney of a rat model of metabolic syndrome.
Topics: AMP-Activated Protein Kinases; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Channel Blo | 2010 |
Effect of losartan on vascular function in fructose-fed rats: the role of perivascular adipose tissue.
Topics: Acetylcholine; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Di | 2010 |
[The normalized smoothness index and parametric population RDH index of losartan in patients with newly diagnosed hypertension and metabolic syndrome].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Pressure Mon | 2010 |
Losartan and pioglitazone ameliorate nephropathy in experimental metabolic syndrome rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Blotting, Western; DNA Primers; Enz | 2011 |
Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blo | 2012 |
A single oral dose of fructose induces some features of metabolic syndrome in rats: role of oxidative stress.
Topics: Administration, Oral; Animals; Blood Glucose; Blood Pressure; Dose-Response Relationship, Drug; Fruc | 2013 |
Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP kinase, and matrix expressions in obesity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chemokine CCL2; Collagen; Extracellular Matrix; Fi | 2005 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study.
Topics: Aged; Cardiovascular Diseases; Electrocardiography; Female; Humans; Hypertension; Hypertrophy, Left | 2007 |
Comparison of vasculoprotective effects of benidipine and losartan in a rat model of metabolic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; Calcium | 2008 |